<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805350</url>
  </required_header>
  <id_info>
    <org_study_id>EFC10844</org_study_id>
    <secondary_id>2008-003791-22</secondary_id>
    <nct_id>NCT00805350</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties</brief_title>
  <acronym>ECLIPSE</acronym>
  <official_title>Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties: a 6-week, Randomized, Double-blind, Placebo-controlled, Polysomnography Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      - To assess the efficacy of eplivanserin 5mg/day in comparison to placebo after 6 weeks of&#xD;
      treatment on sleep maintenance of insomniac patients, as measured by Polysomnography Wake&#xD;
      Time After Sleep Onset (PSG-WASO) and Polysomnography Number of Awakenings (PSG-NAW).&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To evaluate the effects of eplivanserin 5mg/day as compared to placebo after 6 weeks of&#xD;
           treatment on other sleep parameters measured by PSG recordings (Total Sleep Time -&#xD;
           PSG-TST, Sleep Efficiency - PSG-SE, Latency to Persistent Sleep - PSG-LPS) and reported&#xD;
           by patients (Wake Time After Sleep Onset - pr-WASO, Number of Awakenings - pr-NAW, Total&#xD;
           Sleep Time - pr-TST, Quality of Sleep - QoS and Refreshing Quality of Sleep - RqoS).&#xD;
&#xD;
        -  To evaluate the effects of eplivanserin 5mg/day on sleep architecture compared to&#xD;
           placebo.&#xD;
&#xD;
        -  To evaluate the effect of eplivanserin 5mg/day on daytime functioning using the Sleep&#xD;
           Impact Scale (SIS), as compared with placebo after 6 weeks of treatment.&#xD;
&#xD;
        -  To evaluate patient's impression of treatment effects using the Patient's Global&#xD;
           Impression questionnaire.&#xD;
&#xD;
        -  To evaluate the potential for next-day residual effects (using patient's morning&#xD;
           questionnaire and psychometric tests) with eplivanserin 5mg/day as compared to placebo.&#xD;
&#xD;
        -  To evaluate the potential for rebound insomnia following abrupt discontinuation of&#xD;
           eplivanserin 5mg/day in comparison with placebo.&#xD;
&#xD;
        -  To evaluate the effect of eplivanserin, compared to placebo, on the quality of life of&#xD;
           patients with primary insomnia using the SF-36 Health Survey.&#xD;
&#xD;
        -  To evaluate the clinical safety and tolerability of eplivanserin 5mg/day compared to&#xD;
           placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized, double-blind, placebo, controlled study with 2 parallel groups Duration of&#xD;
      treatment : 6 weeks&#xD;
&#xD;
      Duration of observation: 9 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline of mean PSG-WASO on N41/N42</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline of mean PSG-NAW on N41/N42</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other PSG sleep parameters: PSG-TST, PSG-SE (TST/Time in Bed), PSG-LPS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported sleep parameters</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global impression (PGI)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep architecture: percentage of time spent in each sleep stage (1, 2, 3-4/SWS, REM), shift to stage 1, shift to wake, stage 1 + WASO, [stages 3&amp;4]/[stage 1 + WASO]).</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Impact Scale (SIS)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Health Survey</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">637</enrollment>
  <condition>Primary Insomnia</condition>
  <arm_group>
    <arm_group_label>Eplivanserin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplivanserin 5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Eplivanserin 5 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplivanserin</intervention_name>
    <description>one 5 mg tablet once a day</description>
    <arm_group_label>Eplivanserin</arm_group_label>
    <other_name>SR46349</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of Eplivanserin one tablet once a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary insomnia based on DSM-IV-TR (Diagnostic and Statistical Manual of&#xD;
             Mental Disorders, Fourth Edition - Text Revisions) criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inpatients.&#xD;
&#xD;
          -  Mean screening PSG-WASO for screening night 1+ screening night 2 &lt; 45 mn, or screening&#xD;
             night with PSG-WASO &lt; 30 mn.&#xD;
&#xD;
          -  Mean screening PSG-TST for screening night 1 + screening night 2 ≥7 hours or ≤3hours.&#xD;
&#xD;
          -  Mean screening PSG-LPS for screening night 1+ screening night 2 &gt; 30 mn.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD CSD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Laval</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <disposition_first_submitted>February 5, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>February 5, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 7, 2016</disposition_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insomnia</keyword>
  <keyword>Sleep Maintenance</keyword>
  <keyword>Polysomnography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>SR 46349B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

